Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topotecan - study Clear all
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

NCT00068484
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride, bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 5, 2026, 5:54 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT03289910
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

NCT00765973
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors
Interventions
Topotecan Liposomes Injection (TLI)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

NCT00003945
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
Indianapolis, Indiana • Des Moines, Iowa • Papillion, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

NCT05153239
View directory record Official record
Conditions
Relapsed Small Cell Lung Cancer
Interventions
Irinotecan, Lurbinectedin, Topotecan
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Chandler, Arizona • Hot Springs, Arkansas • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

NCT00397293
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AT-101, topotecan
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Chronic Convection Enhanced Delivery of Topotecan

NCT03154996
View directory record Official record
Conditions
Gliomas
Interventions
Topotecan, Gadolinium, Synchromed II infusion pumps
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

NCT03236857
View directory record Official record
Conditions
Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions
chemotherapy, venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 5, 2026, 5:54 PM EDT
Recruiting Phase 1 Interventional

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

NCT05101551
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Talazoparib, Topotecan, Gemcitabine
Drug
Lead sponsor
Norman J. Lacayo
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003297
View directory record Official record
Conditions
Ovarian Cancer
Interventions
mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Results available

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988
View directory record Official record
Conditions
Neuroblastoma
Interventions
Lorlatinib, Cyclophosphamide, Topotecan, Filgrastim/pegfilgrastim
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
topotecan/cisplatin, etoposide/cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

NCT00002395
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Topotecan
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 5, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional

Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

NCT00315211
View directory record Official record
Conditions
Mediastinal Neoplasms
Interventions
Intravenous Topotecan, Intravenous Docetaxel
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 5, 2026, 5:54 PM EDT
Recruiting Phase 3 Interventional

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

NCT00698516
View directory record Official record
Conditions
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Interventions
Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

NCT00295243
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
Topotecan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 5, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00006032
View directory record Official record
Conditions
Breast Cancer
Interventions
etoposide, ifosfamide, topotecan hydrochloride, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

NCT00005593
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
carboplatin, fludarabine phosphate, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers

NCT00231855
View directory record Official record
Conditions
Ovarian Neoplasms, Uterine Neoplasms
Interventions
Topotecan and Taxotere
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Sep 5, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

NCT00316186
View directory record Official record
Conditions
Lung Cancer, Small Cell
Interventions
topotecan, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
12
States / cities
Tucson, Arizona • Concord, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 5, 2026, 5:54 PM EDT